Alcatraz Therapeutics being awarded “New Company with more transformative potential” at Bio-Neurosciences 2025

Amsterdam (The Netherlands) – We are excited to share that Stefan Lohmer, ad interim CEO of Alcatraz Therapeutics, recently presented the company at BioNeuroscience 2025 in Amsterdam.

Alcatraz Therapeutics has been honored with the “New Company with more transformative potential” award!

Currently operating in stealth mode, Alcatraz Therapeutics is a preclinical-stage company focused on developing small molecule modulators targeting TDP43 mis-localization and its downstream effects. These innovations hold promise for addressing devastating neurodegenerative diseases with high unmet medical needs, including ALS, FTD, AD, and HD.

Our lead program, designed to correct Stathmin-2 splicing, is in the lead generation stage, while our second program, aimed at promoting TDP43 nuclear retention, is progressing through the Hit Qualification phase.

This recognition underscores our commitment to pioneering breakthroughs in neurodegenerative disease research.

For more details, please go to the Golgi Neuroscience’s Linkedin Page